Core Points - The company, Innovent Biologics (09969.HK), announced that it will release its Q3 2025 report on November 14, 2025 [1] - To provide investors with a comprehensive understanding of its Q3 2025 operational results and financial status, the company plans to hold a performance briefing on the same day from 11:00 AM to 12:00 PM [1] - The briefing will address questions of interest to investors [1]

Core Viewpoint - The company, Innovent Biologics (09969.HK), announced that it will release its Q3 2025 financial report on November 14, 2025, and will hold a performance briefing to discuss the results and address investor concerns [1] Group 1 - The company plans to hold a performance briefing on November 14, 2025, from 11:00 AM to 12:00 PM [1] - The briefing aims to provide investors with a comprehensive understanding of the company's Q3 2025 operational results and financial status [1] - The event will facilitate communication regarding issues of interest to investors [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 InnoCare Pharma Limited 諾誠健華醫藥有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：9969） 诺诚健华医药有限公司 海外監管公告 本公告乃諾誠健華醫藥有限公司（「本公司」）根據香港聯合交易所有限公司證 券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊登之《關於召開2025年第三季度業績說 明會的公告》。 承董事會命 諾誠健華醫藥有限公司 主席兼執行董事 崔霽松博士 香港，二零二五年十一月五日 於本公告日期，董事會包括主席兼執行董事崔霽松博士；執行董事趙仁濱博士；非執行董事 施一公博士及謝榕剛先生；以及獨立非執行董事胡蘭女士、董丹丹博士及管坤良教授。 | A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-037 | | --- | --- | --- | --- | | 港股代码：09969 ...

致：香港交易及結算所有限公司 公司名稱: 諾誠健華醫藥有限公司（於開曼群島註冊成立的有限公司） 呈交日期: 2025年11月5日 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 | U ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 呈交日期: 2025年11月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09969 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 25,000,000,000 | USD | | 0.000002 | USD | | 50,000 | 本月底法定/註冊股本總額： USD ...

| A | 股代码：688428 | 股简称：诺诚健华 A | 公告编号：2025-037 | | --- | --- | --- | --- | | 港股代码：09969 | | 港股简称：诺诚健华 | | 诺诚健华医药有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 14 日(星期五)上午 11:00-12:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 7 日(星期五)至 11 月 13 日(星期四)16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 IR@innocarepharma.com 进行提问。公司将在说明会上对投资者普遍关注的问题 进 ...

Core Insights - The establishment of the Overseas Returnee Town in Guangzhou's Huangpu District has attracted around 30 well-known innovative enterprises and projects, creating a vibrant entrepreneurial ecosystem for returnees [3][5][11] - The region has developed a complete biopharmaceutical industry chain, facilitating research, transformation, and production, which supports companies at various stages of development [3][5][11] - The "1+N" multi-core model of the town promotes regional collaboration and has become a hub for returnee talent to start their businesses [4][5] Industry Development - The core area of the Overseas Returnee Town spans 3.8 square kilometers, with an additional 4.2 square kilometers for future expansion, forming a comprehensive biopharmaceutical innovation ecosystem [5] - Leading companies such as BeiGene, CanSino Biologics, and Innovent Biologics have established a presence in the town, contributing cutting-edge ideas and technologies while attracting more overseas talent [5][6] - The dual-center support system, including the Phoenix Valley Returnee Center and the International Biopharmaceutical Innovation Center, provides comprehensive services for the ecosystem [5][6] Talent and Investment - The returnee town is strategically aligned with the industrial upgrade of Guangzhou, which has recognized the potential of the biopharmaceutical sector since the late 1990s [7][8] - The government has implemented innovative models combining physical space provision, talent attraction, and market-oriented management, with a guiding fund of 2 billion yuan aimed at attracting social capital [8] - Approximately 76.11 billion yuan has been invested in 274 enterprises, with 18.54 billion yuan specifically directed towards returnee startups [11] Innovation and Collaboration - The Guangzhou National Laboratory on the Biopharmaceutical Island has successfully attracted high-level researchers from abroad, facilitating the transformation of research outcomes into industry applications [9] - The region is focusing on international collaborations, leveraging its advantages in scientific research to establish a leading position in biopharmaceutical innovation [8][9] - The integration of various resources has created a robust innovation network, with around 4,800 biopharmaceutical companies thriving in the area [11]

Core Insights - The establishment of the Overseas Returnee Town (Guangzhou Biomedicine) in the Guangzhou Development Zone and Huangpu District has become a hub for returning talents and innovative enterprises in the biomedicine sector, showcasing a successful model for attracting overseas professionals [1][8][10] Group 1: Development of the Biomedicine Industry - The Guangzhou Development Zone and Huangpu District have built a complete biomedicine industry chain, integrating research, transformation, and production across different areas [1][4] - The core area of the Overseas Returnee Town has attracted around 30 well-known innovative enterprises, creating a positive cycle of talent and industry [3][4] - The "1+N" multi-core model of the town promotes regional collaboration and serves as a crucial hub for innovation [7][10] Group 2: Infrastructure and Support Systems - The dual centers, Phoenix Valley Overseas Returnee Center and International Biomedicine Innovation Center, provide comprehensive support services for the ecosystem [3][4] - The Guangzhou Guigu Technology Park serves as a demonstration area for the Overseas Returnee Town, focusing on innovation and entrepreneurship [4][6] - The establishment of a 20 billion yuan operational management guiding fund aims to attract social capital and enhance the development of the biomedicine sector [10][14] Group 3: Talent Attraction and Retention - The region has successfully attracted returning talents by offering favorable entrepreneurial policies and a conducive environment for innovation [8][10] - The integration of overseas talents into the local innovation network is facilitated by a ten-service operational system [6][12] - The returnee town is designed to support the rapid transformation of scientific achievements into marketable products [4][12] Group 4: Financial Support and Investment - A 50 billion yuan science and technology mother fund has been established to invest in strategic emerging industries, including those involving returning talents [13][14] - Approximately 76.11 billion yuan has been invested in 274 enterprises, with 18.54 billion yuan specifically allocated to returning entrepreneurial companies [14] - The innovative financial model allows for a 100% loss on single projects, effectively reducing early-stage investment risks [13][14]

Core Viewpoint - Nocera Biopharma's stock price has experienced significant fluctuations, with a year-to-date increase of 94.06%, but a recent decline in the last 20 and 60 days, indicating volatility in investor sentiment and market performance [2][3]. Company Overview - Nocera Biopharma, established on November 3, 2015, and listed on September 21, 2022, is based in Beijing and focuses on the research, production, and commercialization of biopharmaceuticals, particularly in oncology and autoimmune diseases [2]. - The company's revenue composition includes 87.67% from drug sales, 12.04% from technology licensing, and minimal contributions from testing and R&D services [2]. Financial Performance - For the first half of 2025, Nocera Biopharma reported a revenue of 731 million yuan, reflecting a year-on-year growth of 74.26%, while the net profit attributable to shareholders was a loss of 30.09 million yuan, an improvement of 88.51% compared to the previous period [3]. Shareholder Structure - As of June 30, 2025, the number of shareholders increased by 13.80% to 15,200, with significant changes in the top ten shareholders, including new entries and exits among institutional investors [3].

Core Insights - The innovation process in the pharmaceutical industry is extremely challenging, with an average time of 10 years and a cost of 1 billion USD from target discovery to market launch, while the success rate is less than 10% [1] Company Insights - 诺诚健华 has been recognized for its innovative journey over the past decade, highlighting the importance of continuous research and development in the pharmaceutical sector [1] - The company benefits from the supportive research policies and industrial ecosystem in Beijing, which provide a conducive environment for growth [1] Industry Insights - China's innovative drugs have become a part of global innovation, representing a new form of productive force in the industry [1]